RWOD

Redwoods Acquisition Corp

NASDAQ

Add Alert

RWOD

Redwoods Acquisition Corp

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

retireat40 Free

04/22/24 6:39 PM

Post #34

Re: #24: @JCESOSA - It is happening. Let’s just wait for April 1st

April 1st came and went. Maybe May 1st

Hugie

04/22/24 9:38 AM

Post #33

Re: #30: @retireat40 - When is the ticker change?

By the end of May probably.

Awl416

04/22/24 7:08 AM

Post #32

Scary

retireat40 Free

04/22/24 7:07 AM

Post #31

Re: #27: @JCESOSA - RWOD closed yesterday at 7.99 and now premarket

Premarket today back to 8. What a POS.

retireat40 Free

04/19/24 6:55 PM

Post #30

Re: #24: @JCESOSA - It is happening. Let’s just wait for April 1st

When is the ticker change?

retireat40 Free

04/19/24 4:18 PM

Post #29

Re: #27: @JCESOSA - RWOD closed yesterday at 7.99 and now premarket

Didn’t do much after PM.

trader59

04/19/24 2:30 PM

Post #28

So, essentially all of the IPO stock (and the cash in the treasury) is being redeemed, leaving the coffers essentially bare. Seems the common shareholders knew better than the $60M valuation crap on an OTC company trading for a fraction of that with nothing going on. The O/S when it settles will be 3.5M-sh, 9.5M-ish when they give the stock to the ANEW folks (dilution), and you'll have a company that hasn't done jack for a couple years with no cash to do anything with, even after the business combination, with 9.5M shares in the O/S at an unknown price. Right out of the gate, they're going to have to do an offering to raise cash.
NASDAQ investors pay attention to business performance. When they see the balance sheet of this combined company with nothing going on and nothing to do it with, they're not going to be lining up to get in on an offering and are going to laugh at the $60M "valuation" RWOD assigned to it.

JCESOSA

04/19/24 7:33 AM

Post #27

RWOD closed yesterday at 7.99 and now premarket is up at 12.78. 1.2 million shares! Crazy.

Awl416

04/19/24 7:19 AM

Post #26

And just like that

Awl416

04/19/24 5:33 AM

Post #25

Crazy whoever is buying up here

The recent spacs sure haven’t done well after ticker change

JCESOSA

03/28/24 7:48 AM

Post #24

It is happening. Let’s just wait for April 1st

misterfishman Free

11/14/23 10:35 AM

Post #23

they have to pay $60000 per month to extent this merger, I don't see them dropping it.so it will happen.

WingCityMan Free

11/02/23 1:59 PM

Post #22

$RWOD $LEAS DEF 14A
https://www.sec.gov/Archives/edgar/data/1907223/000121390023082438/def14a1023_redwoods.htm

WingCityMan Free

10/17/23 4:36 PM

Post #21

$RWOD $LEAS 10/17 S4
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001907223/000101376223004459/fs42023a1_redwood.htm

Bullish

WingCityMan Free

10/16/23 4:11 PM

Post #20

$RWOD filed 14A
https://www.sec.gov/Archives/edgar/data/1907223/000101376223004108/ea186816-pre14a_redwoods.htm
$LEAS

Bullish

chris6789

09/28/23 12:28 PM

Post #19

Slowly getting some volume......LEAS
Nice Bid building

Bullish

PennyMillions852 Free

09/26/23 9:33 AM

Post #18

Need to get $LEAS on a good run!!!

WingCityMan Free

09/25/23 4:06 PM

Post #17

$RWOD 9/25 updated 8K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001907223/000121390023079137/ea185721-8k_redwoods.htm

Bullish

WingCityMan Free

08/22/23 10:50 AM

Post #16

$RWOD $LEAS Filed 10-Q last night https://www.sec.gov/ix?doc=/Archives/edgar/data/1907223/000121390023069521/f10q0623_redwoodsacq.htm

Bullish

WingCityMan Free

08/22/23 10:32 AM

Post #15

Picking up some volume today 220k

WingCityMan Free

08/15/23 9:49 AM

Post #14

$RWOD 10Q filed this morning
https://www.sec.gov/Archives/edgar/data/1907223/000121390023067293/ea183427-nt10q_redwoods.htm

airwolker

08/09/23 10:23 AM

Post #13

Re: #9: @West2 - Go on anewmeds.com

Rituximab is top-selling oncology drug with sales reaching $8.58 billion.

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00163/full

misterfishman Free

08/09/23 7:10 AM

Post #12

Re: #11: @Zardiw - Nice.....RWOD deserves a board for their shareholders to

true that.

Zardiw

08/08/23 6:59 PM

Post #11

Re: #1: @West2 - WELCOME TO RWOD BOARD

Nice.....RWOD deserves a board for their shareholders to discuss the company........

Z

Bullish

Golden Cross PremiumMember

08/08/23 3:27 PM

Post #10

Re: #9: @West2 - Go on anewmeds.com

For what?

West2

08/08/23 3:26 PM

Post #9

Re: #5: @Golden Cross - SPACs usually loose all their value after the

Go on anewmeds.com

West2

08/08/23 3:15 PM

Post #8

Re: #4: @misterfishman - did you buy leas as well,this board wasn't

I own some leas

Golden Cross PremiumMember

08/08/23 2:56 PM

Post #7

#1 Short play $RWOD

misterfishman Free

08/08/23 2:56 PM

Post #6

Re: #5: @Golden Cross - SPACs usually loose all their value after the

yup nice trading range too.

Golden Cross PremiumMember

08/08/23 2:44 PM

Post #5

SPACs usually loose all their value after the merger... Might be a good Short play here

misterfishman Free

08/08/23 2:29 PM

Post #4

Re: #3: @West2 - Welcome sauna

did you buy leas as well,this board wasn't here yesterday, brand new right.

West2

08/08/23 5:28 AM

Post #3

Re: #2: @Sauna - Second

Welcome sauna

Sauna

08/07/23 11:28 PM

Post #2

Second

West2

08/07/23 9:27 PM

Post #1

WELCOME TO RWOD BOARD

Redwoods Acquisition Corp (RWOD)

Followers	9	Posters	14
Posts (Today)	0	Posts (Total)	34
Created	08/07/23	Type	Free
Moderators

RWOD GET INTO A SPAC WITH ANEWMEDS. ANEWMEDS PURCHASED A SHELL OTC NAME LEAS.
ANEW MEDICAL, INC. has acquired pharmaceutical and biotechnology assets in the medical oncology, biologics, and gene therapy sectors of the pharmaceutical and biotechnology industry.
Anew Medical (anewmeds.com)

Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy

The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Redwoods Acquisition Corp. (Form: S-4, Received: 08/04/2023 17:31:16) (otcmarkets.com)
Redwoods Acquisition Corp. (Form: 425, Received: 06/07/2023 06:03:21) (otcmarkets.com)
Redwoods Acquisition Corp. (Form: 8-K, Received: 06/05/2023 06:04:57) (otcmarkets.com)
CEO

Dr. Sinkule has over 40 years of drug, biologic, and medical device R&D and commercialization experience. This serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and its financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. He has hired and managed both small and large teams of experienced people in pharma and biotech organizations, and managed contract research organizations (“CROs”) and contract development and manufacturing companies (“CDMOs”), working for large and small clients. After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He serves on the Board of two companies, and routinely consults for venture capitalist firms, investment banks, as well as both large and early-stage pharmaceutical and biotech companies.

CBO

Peter Moriarty has extensive experience in the pharmaceutical industry both in the United States and internationally. He was a co-founder of Shire Pharmaceuticals, an international specialty pharmaceutical company acquired by Takeda Pharmaceuticals (TAK: NASDAQ). Until its acquisition, Peter was the Executive Chairman of Prismic Pharmaceuticals, a specialty pharmaceutical company he co-founded in 2011, and where he was also the CEO from 2013 to 2018. Prismic was acquired by FSD Pharma (HUGE: NASDAQ). Peter’s earlier career spanned management positions within Warner-Lambert/ Parke-Davis and Schering- Plough, including leadership positions overseas as well as in the United States. Additionally, he led the Sales Force Automation and Software Products Division at Walsh America (acquired by NDC), and led Corporate Development at Ixsys /Applied Molecular Evolution acquired by Eli Lilly (LLY – NYSE). He was subsequently the founder, Chairman and Chief Executive Officer of iPhysicianNet, Inc. and Clinical Information Network.

CTO

Professor Dr. Chillon is the inventor of the α-Klotho patents and technology know how. He has over 25 years of research experience in several key areas of α-klotho and adeno-associated virus (“AAV”) packaging and gene delivery. Miguel has several associates that work with him to expedite development and further the intellectual properties and scientific publications. He leads the research group on Gene therapy for CNS diseases at Universitat Autonoma De Barcelona and Institucio Catalana De Recerca I Estudis Avancats. Miguel is also the Director of the Viral Vector Production Unit at Vall d’Hebrón Hospital, and serves Chair of the ATMP Platform of European Infrastructure for Translational Medicine.
CMO

Dr. Shalom Hirschman, M.D. is a preeminent research physician, a clinical medical expert, and entrepreneur in infectious diseases, oncology, and cancer supportive care, and is a key consulting advisor to the Company. As a young man, he served as an intern and resident in medicine at the Massachusetts General Hospital and Harvard Medical School, and then went on to a career in molecular biology and virology research at the National Institute of Health (NIH). During his career in medical research, he interacted closely with several Nobel Prize winners including Drs. Berson and Yalow (Nobel Prize for development of radioimmunoassays). He was recruited to The Mount Sinai School of Medicine and The Mount Sinai Hospital in New York City as Head of the Department of Infectious Diseases, and eventually he also became Vice-Chairman and Chairman of the Department of Medicine at Mount Sinai, where he remained for three decades. He still is asked to consult on difficult diagnostic dilemmas like the recent COVID-19 pandemic.